Breaking News Instant updates and real-time market news.

BZUN

Baozun

$35.29

-0.06 (-0.17%)

, AIMT

Aimmune

$29.67

0.51 (1.75%)

08:45
12/09/19
12/09
08:45
12/09/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Baozun (BZUN) 21.90% +0.57, Aimmune Therapeutics (AIMT) 0.72% +0.43, Medifast (MED) 1.23% +0.26, Canopy Growth (CGC) 74.21% +0.25, ProShares Ultra VIX Short Term Futures (UVXY) 1.53% +0.18, ProShares UltraShort DJ UBS Crude Oil (SCO) 5.06% +0.11, BRF S.A. (BRFS) 0.39% +0.11, Energy Transfer (ET) 0.53% +0.11, Revolve Group (RVLV) 13.84% +0.11, and Diamond Offshore (DO) 1.22% +0.09.

BZUN

Baozun

$35.29

-0.06 (-0.17%)

AIMT

Aimmune

$29.67

0.51 (1.75%)

MED

Medifast

$90.67

0.48 (0.53%)

CGC

Canopy Growth

$18.65

0.07 (0.38%)

UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

$15.11

-0.8 (-5.03%)

SCO

Scor ADR

$13.14

-0.3 (-2.23%)

BRFS

BRF S.A.

$8.87

0.22 (2.54%)

ET

Energy Transfer LP

$11.50

-0.1 (-0.86%)

RVLV

Revolve Group

$16.74

-0.46 (-2.67%)

DO

Diamond Offshore

$6.01

0.44 (7.90%)

  • 11

    Dec

BZUN Baozun
$35.29

-0.06 (-0.17%)

11/22/19
FBCO
11/22/19
DOWNGRADE
Target $38
FBCO
Neutral
Baozun downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Tina Long downgraded Baozun to Neutral from Outperform with a $38 price target.
08/05/19
JEFF
08/05/19
INITIATION
Target $59.2
JEFF
Buy
Baozun initiated with a Buy at Jefferies
Jefferies analyst Thomas Chong started Baozun with a Buy rating and $59.20 price target. The analyst expects Baozun to enjoy "fast growth," driven by China's consumption upgrade. The company is riding on the secular story of brand e-commerce in China, says Chong.
AIMT Aimmune
$29.67

0.51 (1.75%)

10/04/19
GSCO
10/04/19
NO CHANGE
Target $14
GSCO
Buy
BLA acceptance a de-risking event for DBV Technologies, says Goldman Sachs
Goldman Sachs analyst Graig Suvannavejh called the FDA's acceptance of DBV Technologies' (DBVT) Biologics License Application for Viaskin Peanut a "de-risking event," especially in light of the uncertainty caused by DBV having previously withdrawn its original BLA at the end of 2018. While investors debate the efficacy of Viaskin Peanut, Suvannavejh sees safety, tolerability and ease of use potentially driving better patient uptake when compared to Aimmune's (AIMT) competing Palforzia. He has a Buy rating on DBV with a $14 price target for the American Depositary Shares.
11/18/19
PIPR
11/18/19
NO CHANGE
Target $60
PIPR
Overweight
Piper sees 'meaningful' potential share upside into Aimmune drug launch
Piper Jaffray analyst Christopher Raymond is "increasingly comfortable" with his bullish thesis on Aimmune Therapeutics after traveling with management. The analyst says he's "much more confident" that Palforzia's launch can meaningfully outperform expectations, both near- and long-term. When coupling this with the stock's 30% short interest, Raymond likes the opportunity for "meaningful" share upside into this drug's late January expected approval and launch. He keeps an Overweight rating on Aimmune with a $60 price target.
10/07/19
HCWC
10/07/19
NO CHANGE
Target $25
HCWC
Buy
DBV filing acceptance a 'constructive step forward,' says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein believes Friday's Biologics License Application acceptance as a "constructive step forward" for DBV Technologies (DBVT) in light of a potential perceived overhang for the program related to the Phase 3 Pepites trial. Despite Viaskin Peanut having displayed significant difference in responder rates compared to placebo in the Phase 3 Pepites trial, the question remains as to how the FDA ultimately perceives Viaskin Peanut not meeting its pre-determined 15% lower bound confidence interval between treatment groups, which was reported at 12.4%, Fein tells investors in a research note. The FDA being receptive to evaluate Viaskin Peanut's data package suggests that that Viaskin may not possibly need an 'efficacy homerun" for potential approval and that the company's approach to data analytics could be acceptable, adds the analyst. He reiterates a Buy rating on DBV shares with a $25 price target. Fein continues to believe the risk of anaphylaxis requiring epinephrine could ultimately help to give an edge to DBV's Viaskin Peanut patch over Aimmune's (AIMT) Palforzia.
10/09/19
PIPR
10/09/19
NO CHANGE
Target $60
PIPR
Overweight
Piper remains buyer of Aimmune shares after hosting management
Piper Jaffray analyst Christopher Raymond remains a buyer of Aimmune Therapeutics shares after hosting an investor day with management. The latest iteration of the bear thesis around Aimmune now argues that issues around treatment logistics, access, and durability of treatment will hamper uptake upon Palforzia approval, Raymond tells investors in a research note. However, the analyst believes that many components of this thesis "will be dispelled." With his survey work boding well for Palforzia uptake and durability, he keeps an Overweight rating on Aimmune with a $60 price target.
MED Medifast
$90.67

0.48 (0.53%)

11/08/19
DADA
11/08/19
DOWNGRADE
Target $74
DADA
Neutral
Medifast downgraded to Neutral from Buy at DA Davidson
DA Davidson analyst Bolton Weiser downgraded Medifast to Neutral from Buy with a $74 price target.
11/08/19
DADA
11/08/19
DOWNGRADE
Target $74
DADA
Neutral
Medifast cut to Neutral at DA Davidson on business disruption
DA Davidson analyst Linda Weiser downgraded Medifast to Neutral from Buy with a price target of $74, down from $250. The analyst says the company's disappointing Q3 results were marked by several business disruptions, including the creation of fake customers through bot-executed credit card fraud and supply chain issues. Weiser notes that the investment story on Medifast has "gone off the rails", modeling flat-to-down revenue for the first 3 quarters of FY20 before "optimisticallly" forecasting return to 20% revenue growth in FY21.
09/23/19
DADA
09/23/19
NO CHANGE
Target $250
DADA
Buy
Medifast CFO confident in 2019 guidance, says DA Davidson
DA Davidson analyst Linda Bolton Weiser keeps her Buy rating and $250 price target on Medifast, saying her discussions with its CFO highlighted the management's confidence in its 2019 guidance. The analyst notes that the company anticipates a re-acceleration of earnings growth in Q4 thanks to the 2% pricing and sequential gross margin lift. Weiser also points to Medifast's new Coach app launches in October in Asia and its roll-out in the U.S. in 2020, which she expects to drive further improvement in productivity that is not currently reflected in her model.
09/17/19
JEFF
09/17/19
NO CHANGE
Target $160
JEFF
Buy
Medifast pullback brings attractive entry point, says Jefferies
The further de-rating in shares of Medifast post the company's Q2 results offers an attractive entry point, especially as buybacks complement the company's underlying sales and margin expansion, Jefferies analyst Stephanie Wissink tells investors in a research note. The analyst is "puzzled" by the price action, noting Medifast has posted consistent quarterly results and that estimates "keep edging higher." Further, she sees the potential for the company to over-deliver on short- and long-term targets. Wissink keeps a Buy rating on Medifast with a $160 price target.
CGC Canopy Growth
$18.65

0.07 (0.38%)

11/20/19
BOFA
11/20/19
UPGRADE
BOFA
Buy
Canopy Growth upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Christopher Carey upgraded Canopy Growth to Buy from Neutral with a price target of CAD24. The analyst notes that the stock has fallen 38% since his downgrade two months ago which pointed to the slowdown in orders and relatively high consensus estimates. Following that decline, Carey states that the bad news has been priced into a "more reasonable" valuation as estimates have come in to become achievable or "even beatable" and inventories have turned leaner.
11/20/19
11/20/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Canopy Growth (CGC) upgraded to Buy from Neutral at BofA/Merrill with analyst Christopher Carey saying the stock has fallen 38% since his downgrade two months ago which pointed to the slowdown in orders and relatively high consensus estimates. 2. Schlumberger (SLB) double upgraded to Buy from Sell at Tudor Pickering. 3. Intelsat (I) upgraded to Outperform from Market Perform at Raymond James with analyst Richard Prentiss saying he believes the ~75% pullback over the past 10 days was first related to speculation, and then the confirmation on Monday morning, that the FCC would run a public vs. private auction for 280 MHz. 4. Paycom (PAYC) upgraded to Outperform from Sector Perform at RBC Capital with analyst Alex Zukin saying that after his travel with the company management, he is turning more confident in its ability to "realize price, improve retention, and drive a long runway of continued market disruption and penetration." 5. Tradeweb Markets (TW) upgraded to Buy from Neutral at Goldman Sachs with analyst Alexander Blostein saying the company's "solid" organic revenue growth and expanding operating margins should drive 15% earnings growth in 2020 and 2021. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/22/19
MKMP
11/22/19
NO CHANGE
MKMP
Canopy Growth, Aurora Cannabis profitability hard to achieve, MKM Partners says
MKM Partners analyst Bill Kirk remains cautious on Canadian Cannabis producers, saying that consensus expectations are still "high as a kite". The analyst notes that the sector has recently rebounded to "prior earnings level share prices", but believes that the assumption of "massive revenue growth with hardly any absolute cost growth" embedded in consensus is "very unlikely". Kirk cites fresh signs of cracks in the Canada market - namely that pricing is down, gaps to illicit aren't closing, and consumption per federal license is contracting - which suggests that the near-term path to profitability looks challenged. Kirk keeps his Neutral rating and CAD23 price target on Canopy Growth (CGC) and Sells rating with CAD3 price target on Aurora (ACB).
12/09/19
CANT
12/09/19
NO CHANGE
Target $18.9
CANT
Neutral
Cantor sees over 66% chance of Constellation bidding for Canopy Growth
Cantor Fitzgerald analyst Pablo Zuanic is surprised it has taken this long for Constellation Brands (STZ) to appoint a new CEO at Canopy Growth (CGC) following the exit of Bruce Linton. Pundits trying to read the tea leaves could make arguments both pro and con regarding whether the probability of a bid for the entire company by Constellation has increased or not, Zuanic tells investors in a research note. For his part, the analyst thinks the probability of Constellation trying to acquire Canopy has increased. However, he admits it is not an easy strategic decision for Constellation given its balance sheet, likely mid- to high-teens earnings dilution from a deal for the 65% of Canopy it does not own, and likely near-term hit to its own share price. Nonetheless, Zuanic assigns a more than two-thirds probability to Constellation putting in a bid for all of the Canopy Growth equity in the near term. On the argument of an improving outlook for the cannabis industry, Constellation could justify a deal, contends the analyst, who has a Neutral rating on Canopy Growth with a C$18.90 price target.
UVXY ProShares Trust Ultra VIX Short Term Futures ETF
$15.11

-0.8 (-5.03%)

SCO Scor ADR
$13.14

-0.3 (-2.23%)

BRFS BRF S.A.
$8.87

0.22 (2.54%)

07/22/19
IBBA
07/22/19
UPGRADE
IBBA
Outperform
BRF S.A. upgraded to Outperform from Market Perform at Itau BBA
07/29/19
SBSH
07/29/19
DOWNGRADE
SBSH
Sell
BRF S.A. downgraded to Sell from Neutral at Citi
Citi analyst Alexander Robarts downgraded BRF S.A. to Sell from Neutral while raising his price target for the shares to R$28 from R$23. The analyst cites valuation for the downgrade as he believes the current multiple is "arguably unsustainable" with the stock up 55% in four months.
09/09/19
HSBC
09/09/19
DOWNGRADE
Target $9.02
HSBC
Hold
BRF S.A. downgraded to Hold from Buy at HSBC
HSBC analyst Alessia Apostolatos downgraded BRF S.A. to Hold from Buy with a price target of $9.02, up from $8.96.
06/13/19
JPMS
06/13/19
UPGRADE
Target $8
JPMS
Overweight
JPMorgan upgrades BRF to Overweight, sees benefits from trade war
JPMorgan analyst Lucas Ferreira upgraded BRF S.A. to Overweight from Neutral with an unchanged price target of $8. The analyst remains constructive on protein stocks as he believes "improving" African swine flu signals over the last couple of months reinforce his expectations of a strong earnings rebound in late 2019 and into 2020. Further, a prolonged trade war increases the chances of China sourcing more protein from South America, likely benefiting BRF S.A., Ferreira tells investors in a research note.
ET Energy Transfer LP
$11.50

-0.1 (-0.86%)

11/19/19
SBSH
11/19/19
NO CHANGE
Target $18
SBSH
Buy
Energy Transfer LP could be taken private at $18 per share, says Citi
Citi analyst Timm Schneider says a "take private'" transaction of Energy Transfer LP could generate a 20%-plus internal rate of return at an $18 per share takeout price, or a 45% premium to the Energy Transfer's 30-day trading price. The analyst updated his analysis following news reports of a potential FBI investigation tied to permitting issues around Mariner East. He keeps a Buy rating on Energy Transfer LP and lowered his price target for the shares to $18 from $20.
09/17/19
RHCO
09/17/19
NO CHANGE
Target $17
RHCO
Hold
SemGroup orice target raised to $17 from $11 at SunTrust
SunTrust analyst Tristan Richardson raised his price target on SemGroup (SEMG) to $17 and kept his Hold rating after Energy Transfer LP (ET) announced plans to acquire the company in a part stock/part cash deal. The "huge premium" of the deal is a "grand slam" for shareholders given the lack of strategic options available to "drastically re-rate leverage" for the company and "dramatically more" than the portfolio is worth, the analyst tells investors in a research note. Richardson sees few regulatory barriers for the deal to close at this time.
09/17/19
WELS
09/17/19
NO CHANGE
Target $17
WELS
Market Perform
SemGroup price target raised to $17 from $10 at Wells Fargo
Wells Fargo analyst Michael Blum raised his price target for SemGroup (SEMG) to $17 from $10 after Energy Transfer LP (ET) announced plans to acquire the company in a part stock/part cash deal. The analyst views the merger as mixed for Energy Transfer LP and a very positive outcome for SemGroup holders. Blum has a Market Perform rating on SemGroup's shares.
09/16/19
SBSH
09/16/19
DOWNGRADE
SBSH
Neutral
SemGroup downgraded to Neutral from Buy at Citi
Energy Transfer (ET) announced an agreement to acquire SemGroup (SEMG) in a unit and cash transaction valued at $17 per share.
RVLV Revolve Group
$16.74

-0.46 (-2.67%)

11/06/19
FBCO
11/06/19
NO CHANGE
Target $38
FBCO
Outperform
Revolve Group warrants valuation premium relative to peers, says Credit Suisse
Credit Suisse analyst Michael Binetti is keeping his Outperform rating and $38 price target on Revolve Group ahead of its Q3 results, saying the company's combination of established profitability and "strong" above 20% revenue growth is "increasingly scarce". The analyst notes that the upcoming quarter result may be less of an upside driver for the stock and warns that List 4 tariffs could limit 2019 guidance, but believes that the incremental risk has been priced in after a 26% decline in the stock price since the company's Q2 earnings call.
11/08/19
RAJA
11/08/19
NO CHANGE
Target $30
RAJA
Outperform
Revolve Group price target lowered to $30 from $40 at Raymond James
Raymond James analyst Aaron Kessler lowered his price target for Revolve Group to $30 from $40 saying the company's Owned brands growth slowed in Q3. This drove higher Owned brands inventory and lower full price sales, which also negatively impacted gross margins, Kessler tells investors in a research note. The analyst, however, believes Revolve Group's valuation remains attractive and he keeps an Outperform rating on the shares.
08/09/19
JEFF
08/09/19
NO CHANGE
Target $65
JEFF
Buy
Revolve Group price target raised to $65 from $60 at Jefferies
Jefferies analyst Randal Konik raised his price target for Revolve Group to $65 from $60 saying the company's Q2 results illustrate "robust" growth in active customers and orders, while its margins continue to rise. The quarter highlights the power of the Revolve platform to both aggregate consumers and influencers and scale profits, Konik tells investors in a research note. He keeps a Buy rating on the shares.
11/12/19
BARD
11/12/19
INITIATION
Target $26
BARD
Outperform
Revolve Group initiated with an Outperform at Baird
Baird initiated coverage of Revolve Group with an Outperform rating and $26 price target.
DO Diamond Offshore
$6.01

0.44 (7.90%)

09/25/19
09/25/19
DOWNGRADE
Target $10

Sector Perform
Diamond Offshore downgraded to Sector Perform from Outperform at RBC Capital
As previously reported, RBC Capital analyst Kurt Hallead downgraded Diamond Offshore to Sector Perform from Outperform and lowered his price target for the shares to $10 from $11. The analyst notes that while activity and pricing have seen signs of "definitive improvement", the pace of recovery has been slower than anticipated, which pushed out the timeline for the company to become free cash flow positive. Hallead still sees Diamond Offshore with the "least capital structure risk" and the most contract visibility within his coverage.
10/24/19
NORD
10/24/19
UPGRADE
NORD
Hold
Diamond Offshore upgraded to Hold from Sell at Nordea
Nordea analyst Janne Kvernland upgraded Diamond Offshore to Hold from Sell.
12/06/19
HSBC
12/06/19
DOWNGRADE
Target $5.7
HSBC
Hold
Diamond Offshore downgraded to Hold from Buy at HSBC
HSBC analyst Abhishek Kumar downgraded Diamond Offshore to Hold from Buy with a $5.70 price target.
10/21/19
FERN
10/21/19
DOWNGRADE
Target $6
FERN
Hold
Diamond Offshore downgraded to Hold from Buy at Fearnley
Fearnley analyst Truls Olsen downgraded Diamond Offshore to Hold from Buy with a $6 price target.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$1,864.40

-13.55 (-0.72%)

07:41
01/21/20
01/21
07:41
01/21/20
07:41
Conference/Events
Amazon.com management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 30

    Jan

  • 10

    Feb

PCRX

Pacira

$43.77

-0.2 (-0.45%)

07:41
01/21/20
01/21
07:41
01/21/20
07:41
Hot Stocks
Pacira, Envision Physician Services collaborate for anesthesia training »

Pacira BioSciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSX

GSX Techedu

$32.97

2.67 (8.81%)

07:40
01/21/20
01/21
07:40
01/21/20
07:40
Initiation
GSX Techedu initiated  »

GSX Techedu initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLCM

Bellicum Pharmaceuticals

$2.28

0.19 (9.09%)

07:40
01/21/20
01/21
07:40
01/21/20
07:40
Hot Stocks
MD Anderson to acquire Bellicum Pharmaceuticals' Houston facility for $15M »

Bellicum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBH

Sally Beauty

$15.27

-0.46 (-2.92%)

07:38
01/21/20
01/21
07:38
01/21/20
07:38
Upgrade
Sally Beauty rating change  »

Sally Beauty upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

STIM

Neuronetics

$4.38

-0.01 (-0.23%)

, SLCA

U.S. Silica

$5.83

0.185 (3.28%)

07:37
01/21/20
01/21
07:37
01/21/20
07:37
Hot Stocks
Neuronetics appoints Andrew Macan as general counsel, CCO, corporate secretary »

Neuronetics (STIM)…

STIM

Neuronetics

$4.38

-0.01 (-0.23%)

SLCA

U.S. Silica

$5.83

0.185 (3.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

LVS

Las Vegas Sands

$74.07

0.67 (0.91%)

, WYNN

Wynn Resorts

$151.51

-0.68 (-0.45%)

07:36
01/21/20
01/21
07:36
01/21/20
07:36
Downgrade
Las Vegas Sands, Wynn Resorts rating change  »

Las Vegas Sands…

LVS

Las Vegas Sands

$74.07

0.67 (0.91%)

WYNN

Wynn Resorts

$151.51

-0.68 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUB

Atlantic Union Bankshares

$36.81

-0.03 (-0.08%)

07:35
01/21/20
01/21
07:35
01/21/20
07:35
Earnings
Atlantic Union Bankshares reports Q4 operating EPS 71c, consensus 70c »

"Atlantic Union…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

EPD

Enterprise Products

$28.80

-0.24 (-0.83%)

07:35
01/21/20
01/21
07:35
01/21/20
07:35
Hot Stocks
Enterprise Products begins service at Mentone natural gas processing plant »

Enterprise Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

SWN

Southwestern Energy

$1.85

-0.09 (-4.64%)

, SWK

Stanley Black & Decker

$172.63

2.18 (1.28%)

07:35
01/21/20
01/21
07:35
01/21/20
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

SWN

Southwestern Energy

$1.85

-0.09 (-4.64%)

SWK

Stanley Black & Decker

$172.63

2.18 (1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

07:35
01/21/20
01/21
07:35
01/21/20
07:35
General news
Treasury Market Outlook: Treasuries have a bid in a safe haven play »

Treasury Market Outlook:…

AAPL

Apple

$318.66

3.33 (1.06%)

07:33
01/21/20
01/21
07:33
01/21/20
07:33
Periodicals
Apple scrapped plan for encrypting backups after FBI complained, Reuters reports »

Apple scrapped plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

MITO

Stealth Biotherapeutics

$3.04

-0.04 (-1.30%)

07:33
01/21/20
01/21
07:33
01/21/20
07:33
Hot Stocks
Stealth Biotherapeutics initiates human Phase 1 trial evaluating SBT-272 »

Stealth BioTherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EHC

Encompass Health

$79.50

-0.77 (-0.96%)

07:31
01/21/20
01/21
07:31
01/21/20
07:31
Hot Stocks
Encompass Health plans to build rehabilitation hospital in South Carolina »

Encompass Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

WPC

W.P. Carey

$83.13

-0.14 (-0.17%)

07:31
01/21/20
01/21
07:31
01/21/20
07:31
Hot Stocks
W.P. Carey announces $112M investment in U.K. Class-A logistics facility »

W. P. Carey announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INGR

Ingredion

$92.58

-0.355 (-0.38%)

, FISV

Fiserv

$120.69

0.46 (0.38%)

07:30
01/21/20
01/21
07:30
01/21/20
07:30
Hot Stocks
Ingredion appoints Tiffany Willis as VP, investor relations »

Ingredion (INGR)…

INGR

Ingredion

$92.58

-0.355 (-0.38%)

FISV

Fiserv

$120.69

0.46 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Feb

  • 17

    Feb

TSLA

Tesla

$510.34

-3.065 (-0.60%)

07:29
01/21/20
01/21
07:29
01/21/20
07:29
Recommendations
Tesla analyst commentary  »

Tesla near-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 24

    Feb

  • 23

    Mar

  • 23

    Mar

ORGS

Orgenesis

$5.40

0.36 (7.14%)

07:28
01/21/20
01/21
07:28
01/21/20
07:28
Hot Stocks
Orgenesis announces $9.2M private placement »

Orgenesis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LAC

Lithium Americas

$4.12

-0.05 (-1.20%)

07:27
01/21/20
01/21
07:27
01/21/20
07:27
Hot Stocks
Lithium Americas receives notice of intent for Thacker Pass lithium project »

Lithium Americas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 12

    Mar

EQT

EQT Corporation

$8.25

-0.28 (-3.28%)

07:27
01/21/20
01/21
07:27
01/21/20
07:27
Upgrade
EQT Corporation rating change  »

EQT Corporation upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VERU

Veru

$4.19

0.07 (1.70%)

07:25
01/21/20
01/21
07:25
01/21/20
07:25
Recommendations
Veru analyst commentary  »

Veru price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUAN

Nuance

$19.74

-0.02 (-0.10%)

07:24
01/21/20
01/21
07:24
01/21/20
07:24
Hot Stocks
Nuance announces Dragon Medical One availability in France, Belgium, Netherlands »

Nuance Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 05

    Feb

MRSN

Mersana Therapeutics

$8.05

0.42 (5.50%)

07:23
01/21/20
01/21
07:23
01/21/20
07:23
Recommendations
Mersana Therapeutics analyst commentary  »

Mersana Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$85.35

-1.66 (-1.91%)

07:22
01/21/20
01/21
07:22
01/21/20
07:22
Upgrade
EOG Resources rating change  »

EOG Resources upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

KMDA

Kamada

$6.62

0.09 (1.38%)

07:21
01/21/20
01/21
07:21
01/21/20
07:21
Hot Stocks
Kamada announces $25M private placement with FIMI Opportunity Fund »

Kamada announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.